Roger S. McIntyre reports grants from Allergan, AstraZeneca, Bristol-Myers, Janssen-Ortho, Lundbeck, Otsuka, Purdue, Pfizer, Shire, Sunovion, Neurocrine, and Takeda outside the submitted work.
Nicole Anderson, Bernhard T. Baune, Katherine Burdick, Phillipe Fossati, Rodrigo B. Mansur, Alice Medalia, Tanya Ramey, and Joshua D. Rosenblat have nothing to disclose.
Elisa Brietzke reports personal fees from Daiichi-Sakyo outside the submitted work.
Philip Gorwood reports grants from Eli Lilly, Ethypharm, and Servier and personal fees from Janssen, Lilly, Lundbeck, Otsuka, and Servier outside the submitted work.
Catherine Harmer reports personal fees from P1vital, Lundbeck, Servier, and Pfizer, grants from UCB, and grants and personal fees from Johnson and Johnson outside the submitted work.
John Harrison reports personal fees from AbbVie, Amgen, Anavex, Astra Zeneca, Avonex, Avraham, Axon Neuroscience, Axovant, Biogen Idec, Boehringer Ingelheim, Bracket, Catenion, CRF Health, DeNDRoN, Eisai, Eli Lilly, Enzymotec, ePharmaSolutions, Forum Pharma, GfHEU, Heptares, Janssen AI, Johnson & Johnson, Kaasa Health, Kyowa Hakko Kirin, MedAvante, Merck, Mind Agilis, MyCognition, Neurim, Neurocog, personal fees and other from Neurotrack, Novartis, Nutricia, Orion Pharma, Pfizer, Pharmanet/i3, Prana Biotech, PriceSpective, Probiodrug, Prophase, Prostrakan, Regeneron, Reviva, Roche, Sanofi, Servier, Takeda, vTv Therapeutics, Velacor, Lundbeck, Compass Pathways, G4X Discovery, Cognition Therapeutics, and AlzeCure outside the submitted work.
Philip Harvey reports personal fees from Akili, Biogen, Allergan, Boehringer-Ingelheim, Forum Pharma, Genentech, Intracellular Therapies, Lundbeck, Minerva Pharma, Otsuka Digital Health, Sanofi, Sunovion (DSP), and Teva, grants and personal fees from Takeda, grants from Stanley Medical Research Foundation, and other from Neurocog Trials during the conduct of the study.
Kamilla Miskowiak reports personal fees from Lundbeck and Allergan outside the submitted work.
Carola Rong reports personal fees from EOCI Pharmacomm outside the submitted work.
Allan Young reports grants from Janssen and personal fees from Lundbeck, Livanova, and Sunovion outside the submitted work.
Stephen M. Stahl reports grants from Acadia, Alkermes, AssureX, Astra Zeneca, Arbor Pharmaceuticals, Avanir, Axovant, Biogen, Braeburn Pharmaceuticals, BristolMyer Squibb, Celgene, CeNeRx, Cephalon, Dey, Eli Lilly, EnVivo, Forest, Forum, GenOmind, Glaxo Smith Kline, Intra-Cellular Therapies, ISSWSH, Janssen, JayMac, Jazz, Lundbeck, Merck, Mylan, Neurocrine, Neuronetics, Novartis, Otsuka, PamLabs, Pfizer, Reviva, Roche, Sepracor, Servier, Shire, Sprout, Sunovion, TMS NeuroHealth Centers, Takeda, Teva, Tonix, Vanda, Valeant and Wyeth and personal fees from Acadia, Adamas, Alkermes, Allergan, Arbor Pharmaceutcials, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene,Concert, ClearView, DepoMed, Dey, EnVivo, Ferring, Forest, Forum, Genomind. Innovative Science Solutions, Intra-Cellular Therapies, Janssen, Jazz, Lilly, Lundbeck, Merck, Neos, Novartis, Noveida, Orexigen, Otsuka, PamLabs, Perrigo, Pfizer, Pierre Fabre, Reviva, Servier, Shire, Sprout, Sunovion, Taisho, Takeda, Taliaz, Teva, Tonix, Trius, Vanda, and Viforpharma, and other from RCT Logic and Genomind outside the submitted work.
1. McIntyre, RS, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013; 30(6): 515–527.
2. Millan, MJ, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012; 11(2): 141–168.
3. Murray, CJL, Lopez, AD. Measuring global health: motivation and evolution of the Global Burden of Disease Study. Lancet. 2017; 390(10100): 1460–1464.
4. Razzouk, D. Mental Health Economics: The Costs and Benefits of Psychiatric Care. Springer, 2017.
5. Insel, TR. Assessing the economic costs of serious mental illness. Am J Psychiatry. 2008; 165(6): 663–665.
6. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1260–1344.
7. Sokratis, P, Ion, B, Alexandra, E, et al. Cognition and driving behavior in neurodegenerative disorders. Front Hum Neurosci. 2016; 10.
8. Greenberg, PE, FournierA-A, , Sisitsky, T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155–162.
9. McIntyre, RS, et al. The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Ther Adv Chronic Dis. 2016; 7(3): 153–159.
10. Lee, Y, et al. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review. J Affect Disord. 2017; 227: 406–415.
11. Baune, BT, Malhi, GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015; 17(suppl 2): 41–55.
12. Baune, BT, Renger, L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression—a systematic review. Psychiatry Res. 2014; 219(1): 25–50.
13. Vinberg, M, Miskowiak, KW, Kessing, LV. Impairment of executive function and attention predicts onset of affective disorder in healthy high-risk twins. J Clin Psychiatry. 2013; 74(8): e747–53, Aug. 2013.
14. Miskowiak, KW, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2017; 19(8): 614–626.
15. Papakostas, GI, Culpepper, L. Understanding and managing cognition in the depressed patient. J Clin Psychiatry. 2015; 76(4): 418–425.
16. McIntyre, RS, Lee, Y, Mansur, RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015; 20(suppl 1): 20–30; quiz 31.
17. Culpepper, L. Improving patient outcomes in depression through guideline-concordant, measurement-based care. J Clin Psychiatry. 2013; 74(4): e07.
18. Insel, T, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 20101; 167(7): 748–751.
19. McTeague, LM, Huemer, J, Carreon, DM, et al. Identification of common neural circuit disruptions in cognitive control across psychiatric disorders. Am J Psychiatry. 2017; 174(7): 676–685.
20. McTeague, LM, Goodkind, MS, Etkin, A. Transdiagnostic impairment of cognitive control in mental illness. J Psychiatr Res. 2016; 83: 37–46.
21. Lin, GR, McCormick, JI, Dhe-Paganon, S, et al. Role of specific acidic lipids on the reconstitution of Na(+)-dependent amino acid transport in proteoliposomes derived from Ehrlich cell plasma membranes. Biochemistry. 1990; 29(19): 4575–4581.
22. Insel, TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014; 171(4): 395–397.
23. McIntyre, RS, Johe, K, Rong, C, Lee, Y. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opin Investig Drugs. 2017; 26(6): 767–770.
24. McIntyre, RS. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther. 2014; 31(3): 245–246.
25. McIntyre, RS, Lee, Y. Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI). Curr Opin Psychiatry. 2016; 29(1): 48–55.
26. Doran, CM, Kinchin, I. A review of the economic impact of mental illness. Aust Health Rev. 2017. doi: 10.1071/AH16115.
27. Patel, V, et al. Global priorities for addressing the burden of mental, neurological, and substance use disorders. In Patel V, Chisholm D, Dua T, et al., eds. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities. Vol. 4. 4th ed. Washington, DC: International Bank for Reconstruction and Development/World Bank; 2016.
28. Paddick, S-M, Gray, WK, McGuire, J, et al. Cognitive screening tools for identification of dementia in illiterate and low-educated older adults, a systematic review and meta-analysis. Int Psychogeriatr. 2017; 29(6): 897–929.
29. Sheffield, JM, et al. Transdiagnostic associations between functional brain network integrity and cognition. JAMA Psychiatry. 2017; 74(6): 605–613.
30. McIntyre, RS, Cha, DS, Soczynska, JK. Cognition in Major Depressive Disorder. 2014.
31. McCoy, TH, Castro, VM, Rosenfield, HR, et al. A clinical perspective on the relevance of research domain criteria in electronic health records. Am J Psychiatry. 2015; 172(4): 316–320.
32. Pranckeviciene, A, Deltuva, VP, Tamasauskas, A, Bunevicius, A. Association between psychological distress, subjective cognitive complaints and objective neuropsychological functioning in brain tumor patients. Clin Neurol Neurosurg. 2017; 163: 18–23.
33. Cacciamani, F, et al. Low cognitive awareness, but not complaint, is a good marker of preclinical Alzheimer’s disease. J Alzheimers Dis. 2017; 59(2): 753–762.
34. Srisurapanont, M, Suttajit, S, Eurviriyanukul, K, Varnado, P. Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep. 2017; 7(1); 3901.
35. Golan, D, et al. The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Mult Scler. 2018; 24(2): 196–204.
36. Mansur, RB, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018; 30(1): 38–50.
37. Demant, KM, Vinberg, M, Kessing, LV, Miskowiak, KW. Assessment of subjective and objective cognitive function in bipolar disorder: correlations, predictors and the relation to psychosocial function. Psychiatry Res. 2015; 229(1–2): 565–571.
38. Kinsinger, SW, Lattie, E, Mohr, DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology. 2010; 24(5): 573–580.
39. Ott, CV, et al. Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools. J Affect Disord. 2016; 190: 607–615.
40. Shi, C, et al. Reliability and validity of Chinese version of perceived deficits questionnaire for depression in patients with MDD. Psychiatry Res. 2017; 252: 319–324.
41. Ventura, J, et al. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res. 2010; 121(1–3): 24–31.
42. Richards, M, Wadsworth, MEJ. Long term effects of early adversity on cognitive function. Arch Dis Child. 2004; 89(10): 922–927, 2004.
43. Kumar, RG, Gao, S, Juengst, SB, et al. The effects of post-traumatic depression on cognition, pain, fatigue, and headache after moderate-to-severe traumatic brain injury: a thematic review. Brain Inj. 2018; 32(4): 383–394.
44. Roiser, JP, Sahakian, BJ. Hot and cold cognition in depression. CNS Spectr. 2013; 18(3): 139–149.
45. McIntyre, RS, Cha, DS, Soczynska, JK. “Hot” versus “cold” cognition. In Cognition in Major Depressive Disorder. 2014: 21–30.
46. Fenesy, MC, Lee, SS. Association of ADHD and executive functioning with childhood depression. J Atten Disord. 2017; 108705471772398.
47. Ritchie, M, Yeap, BB. Thyroid hormone: influences on mood and cognition in adults. Maturitas. 2015; 81(2): 266–275.
48. Mansur, RB, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: a meta-analysis. Ann Clin Psychiatry. 2018; 30(1): 38–50.
49. Lowe, CJ, Safati, A, Hall, PA. The neurocognitive consequences of sleep restriction: a meta-analytic review. Neurosci Biobehav Rev. 2017; 80: 586–604.
50. Hindmarch, I. Cognition and anxiety: the cognitive effects of anti-anxiety medication. Acta Psychiatr Scand. 1998; 98(suppl 393): 89–94.
51. Qidwai, JC, Watson, GS, Weiler, JM. Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep. 2002; 2(3): 216–222.
52. Ieong, HF-H, Yuan, Z. Resting-state neuroimaging and neuropsychological findings in opioid use disorder during abstinence: a review. Front Hum Neurosci. 2017; 11:169.
53. Potvin, S, Pelletier, J, Grot, S, et al. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. 2018; 80: 154–160.
54. Giorgetti, R, Marcotulli, D, Tagliabracci, A, Schifano, F. Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. Forensic Sci Int. 2015; 252: 127–142.
55. Carliner, H, Brown, QL, Sarvet, AL, Hasin, DS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017; 104: 13–23.
56. Volkow, ND, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016; 73(3): 292–297.
57. Rong, C, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017; 121: 213–218.
58. Harrison, JE, Lam, RW, Baune, BT, McIntyre, RS. Selection of cognitive tests for trials of therapeutic agents. Lancet Psychiatry. 2016; 3(6); 499.
59. Baune, BT, et al. Cognition in depression: can we THINC-it better? J Affect Disord. 2018; 225: 559–562.
60. Ragguett, R-M, Cha, DS, Kakar, R, et al. Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health. 2016; 19(4): 106–109.
61. Miskowiak, KW, et al. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord. 2018; 20(3): 184–194.
62. Freitas, S, Santana, I, Simoes, MR. The sensitivity of the MoCA and MMSE to cognitive decline: a longitudinal study. Alzheimers Dement. 2010; 6(4): S353–S354.
63. Julayanont, P, Nasreddine, ZS. Montreal Cognitive Assessment (MoCA): concept and clinical review. In Larner AJ, ed. Cognitive Screening Instruments. London: Springer; 2016: 139–195.
64. Finney, GR, Minagar, A, Heilman, KM. Assessment of mental Status. Neurol Clin. 2016; 34(1): 1–16.
65. Baune, BT, Miller, R, McAfoose, J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010; 176(2–3): 183–189.
66. Lai, CYY, Ho, CSH, Lim, CR, Ho, RCM. Functional near-infrared spectroscopy in psychiatry. BJPsych Advances. 2017; 23(5): 324–330.
67. Rogan, S, Lippa, CF. Alzheimer’s disease and other dementias: a review. Am J Alzheimers Dis Other Demen. 2002; 17(1): 11–17.
68. Pan, Z, et al. Pharmacological treatment of cognitive symptoms in major depressive disorder. CNS Neurol Disord Drug Targets. 2017; 16(8): 891–899.
69. Chan, S, Godwin, H, Gonzalez, A, et al. Review of use and integration of mobile apps into psychiatric treatments. Curr Psychiatry Rep. 2017; 19(12); 96.